Insomnia – Access & Reimbursement – Detailed, Expanded Analysis (US)
Insomnia is a highly prevalent condition with obvious indirect economic costs, but payers may not be fully aware of the healthcare cost savings that could result from ensuring patient access to effective insomnia treatment. In recent history, market access factors have not been a major constraint for physicians prescribing pharmacotherapies for the treatment of insomnia, because the majority of drugs in the insomnia market are available as inexpensive generic products. However, marketers of emerging insomnia brands such as Eisai’s Dayvigo (lemborexant) will need to understand how payers view the cost-effectiveness of branded insomnia therapies in order to ensure continued favorable reimbursement.
QUESTIONS ANSWERED
- How do surveyed payers reimburse available insomnia therapies? What restrictions do they impose on branded products, such as Merck’s dual orexin receptor antagonist (DORA) Belsomra (suvorexant)? How do market access dynamics influence physician prescribing of pharmacotherapies for the treatment of insomnia?
- How will emerging therapies be reimbursed, especially additional members of the DORA drug class? How valuable is long-term efficacy and safety data in chronic insomnia patients to physicians and payers, given that most insomnia therapies have been approved based on only short-term clinical trials?
- What actions can marketers and developers of insomnia therapies take to succeed in terms of market access and therefore overall sales or use?
CONTENT HIGHLIGHTS
Geography: United States
Primary Research: Survey of 51 U.S. PCPs and 50 U.S. psychiatrists; Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs / MDs)
Fingertip formulary: Formulary coverage and restrictions data for insomnia therapies by commercial plans covering approximately 166 million lives nationally and and Medicare Advantage with prescription drug plans (MAPDs) covering almost 15 million lives.
Key Drugs Covered: Belsomra, Silenor, zolpidem, eszopiclone, trazodone, ramelteon, Dayvigo
Content highlights:
Reimbursement and contracting
Access and prescribing
Opportunities and challenges for emerging therapies
Disease-specific special topic
PRODUCT DESCRIPTION
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.
Table of contents
- Insomnia - Access & Reimbursement - Detailed, Expanded Analysis (US)
- Access & Reimbursement Insomnia US June 2020
Natalie Taylor, Ph.D., is a principal business insights analyst on the CNS/Ophthalmology Disorders team at Clarivate. She has more than ten years of experience authoring primary and market research reports for pharmaceutical industry clients in the fields of psychiatry, pain, neurology, and ophthalmology. Previously, Dr. Taylor worked at QuintilesIMS as manager of its CNS portfolio. She completed her Ph.D. in physiology at Dartmouth College in New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a B.S. in biology from Dickinson College in Pennsylvania.
Chris Lewis is a primary research manager at Clarivate. She is responsible for the coordination, content review, and content generation of U.S. Access & Reimbursement reports, including authoring select A&R reports on managed care trends. Before this position, Ms. Lewis was a senior analyst at HealthLeaders-InterStudy. She analyzed the managed care markets in California, New York, and Pennsylvania. She also launched and authored the Pharmacy Benefit Manager profile series. She received her bachelor’s degree from California State University in Sacramento.